

Pfizer EBMT 2022 hybrid symposium

Tuesday 22 March, 2022 | 12:45–13:45 (CET)
Forum Hall, 2nd Floor, Prague Congress Centre
Remotely in Virtual Hall 2

Prophylaxis versus diagnostic-driven therapy: Best-practice approaches for treating IMD in haematology patients



Agenda

Chair: Dr Alexander Schauwvlieghe (Belgium)

-
- 12:45–12:50 CET »** **Welcome and introduction**
Alexander Schauwvlieghe (Belgium)
-
- 12:50–13:05 CET »** **Aspergillosis in the haematology unit from an ID perspective:
Early suspicion and diagnostic-driven management**
Isabel Ruiz-Camps (Spain)
-
- 13:05–13:20 CET »** **Aspergillosis in the haematology unit:
Complex patients and prophylaxis**
Alexander Schauwvlieghe (Belgium)
-
- 13:20–13:35 CET »** **The changing therapeutic landscape of IMD:
The role of existing and upcoming antifungals**
Cornelia Lass-Flörl (Austria)
-
- 13:35–13:45 CET »** **Discussion, Q&A and close**
All faculty
-

ID, infectious disease; IMD, invasive mould disease



PP-CRB-GLB-0873

Date of preparation: February 2022

©2022 Pfizer Inc. All rights reserved.

 **EBMT 48th Annual Meeting**
19–23 March 2022 | Prague Hybrid

Pfizer, spol. s r.o., Stroupežnického 17, 150 00, Praha 5
Tel.: +420 283 004 111, fax +420 251 610 270, www.pfizer.cz

Before prescribing Pfizer medicinal products, please refer to the full Summary of Product Characteristics (SmPCs). Please refer to your local authorities concerning reimbursement status. Medicinal products subject to medical prescription.